1Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer:report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study [ J ]. J Natl Cancer inst, 1998,90(18) : 1 371-1 388.
2Milla-Santos A,Milla L,Rallo L,et al. phase Ⅲ randomized trial of toremifene vs tamoxifen in hormonodependent advanced breast cancer [ J ]. Breast Cancer Res Treat,2001,65 (2) : 119 - 124.
3Cummings SR, Eckert S, Krueget KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women : results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation [ J]. TAMA ,1999,281 (23) :2189 - 2197.
4Bross PF, Baird A. Chen G, et al. Fulvestrant in postmenopausal women with advanced breast cancer [ J ]. Clin Cancer Res, 2003,9 (12) :4 309-4 317.
5Dombernowsky P, Smith 1 Falkson G, et al, letrozole, a new oral aromatase inhibitor for advanced breast cancer;double-blind randomised trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate[ J]. J Clin Oncol,1998,16(2) :453 -461.
6Lonning PE, Bajetta E, Murray R,et al. Activity of exemestane in metastastic breast cancer after failure of nonsteroidal aromatase inhibitors:a phase Ⅱ trial[J]. J Clin Oncol,2000,18( 11 ) :2234 -2244.
7Mouridsen H, Cershanovieh M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first line therapy for postmenopausal women with advanced breast cancer:results of a phase Ⅲ study of the international letrozole breast cancer group[ J]. J Clin Oncol,2001,19 (10) :2 596 -2 606.
8Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first line therapy for advanced breast cancer in pestmenopausal women:results of a North American multicenter randomised trial. Arimidex Study Group[ J ]. J Clin Oncol,2000,18 ( 22 ) : 3758-3 767.
9Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first line therapy for advanced breast cancer in 668 postmenopausal women : results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study [ J]. J Clin Oncol, 2000, 18 (22) :3 748 -3 757.
10ATAC Trailist'Groop. Resalts of the ATAC ( Arimidex. tamoxifen Alone, or in combination ) trial after completion of 5-years' adjuvant treatment for breast cancer[J]. lancet,2005. 365(9453) :60-62.
6Weiss JR,Moysich KB,Swede H.Epidemiology of male breast cancer[J].Cancer Epidemiology,Biomarkers & Prevention,2005,14(1):20-26.
7Giordano SH,Cohen DS,Buzdar AU,et al.Breast carcinoma in men:a population-based study[J].Cancer,2004,101(1):51-57.
8Scott-Conner CE,Jochimsen PR,Menck HR,et al.An analysis of male and female breast cancer treatment and survival among demographically identical pairs of patients[J].Surgery,1999,126(3):775-780.
9Evans GF,Anthony T,Turnage RH,et al.The diagnostic accuracy of mammography in the evaluation of male breast disease[J].Am J Surg,2001,181(1):96-100.
10Akikoioka,HideakiTsukuma,WakikoAjik,et al.Survival of male breast cancer patients:a population-based study in osaka,japan[J].Jpn J Clin Oncol,2006,36(3):699-701.
